Healthy control nose blood

Healthy control nose blood - HCNB

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51830

Enrollment

100

Registered

2022-10-25

Start date

2023-02-10

Completion date

Unknown

Last updated

2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alle deelnemers zijn gezond -

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Age >= 18 years old - not included in ongoing clinical studies - Signed informed-consent

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - refusal of participation - known respiratory or autoimmune disease - treatment with immune suppression

Design outcomes

Primary

Measure	Time frame
Expression levels of inflammatory markers expressed on epithelial and immune cells, abundance of a particular pathogenic cell type in peripheral blood or plasma levels of inflammatory proteins like cytokines. The inflammatory response of epithelial cells in vitro to pathogens and the interplay between the epithelial cells and immune cells obtained from blood in in vitro co-cultures. Outcomes of these parameters will be a direct comparison to the outcomes of the TERRIFIC study.	—

Measure

Time frame

Expression levels of inflammatory markers expressed on epithelial and immune cells, abundance of a particular pathogenic cell type in peripheral blood or plasma levels of inflammatory proteins like cytokines. The inflammatory response of epithelial cells in vitro to pathogens and the interplay between the epithelial cells and immune cells obtained from blood in in vitro co-cultures. Outcomes of these parameters will be a direct comparison to the outcomes of the TERRIFIC study.

—

Countries

Netherlands

Outcome results